NCT07317323 Norwegian Spontaneous Coronary Artery Dissection Study
| NCT ID | NCT07317323 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Oslo University Hospital |
| Condition | SCAD |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2025-04-01 |
| Primary Completion | 2035-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2025-04-01 with a primary completion date of 2035-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The Norwegian Spontaneous Coronary Artery Dissection Study (NOR-SCAD) is a national, multicenter prospective observational study conducted at major hospitals in Norway. The study investigates risk factors and complications of spontaneous coronary artery dissection (SCAD). Patients aged 18 years or older who are hospitalized with SCAD are recruited during the index hospitalization. Each participant will be followed for 52 weeks with scheduled visits at 8 and 12 weeks and a final phone call at 52 weeks. Evaluations include coronary CT angiography (CTA), cardiac assessments, genetic analyses, blood sampling, structured questionnaires, and a cardiopulmonary exercise test (CPET).
Eligibility Criteria
Inclusion Criteria: * Spontaneous coronary artery dissection Exclusion Criteria: * Severe kidney failure * Severe allergic reaction to contrast
Contact & Investigator
Mette Elise Estensen, MD., PhD
PRINCIPAL INVESTIGATOR
ProCardio, Kardiologisk avdeling Rikshospitalet, Oslo Univeristy Hospital
Frequently Asked Questions
Who can join the NCT07317323 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying SCAD. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07317323 currently recruiting?
Yes, NCT07317323 is actively recruiting participants. Contact the research team at anloso@ous-hf.no for enrollment information.
Where is the NCT07317323 trial being conducted?
This trial is being conducted at Bergen, Norway, Oslo, Norway, Oslo, Norway.
Who is sponsoring the NCT07317323 clinical trial?
NCT07317323 is sponsored by Oslo University Hospital. The principal investigator is Mette Elise Estensen, MD., PhD at ProCardio, Kardiologisk avdeling Rikshospitalet, Oslo Univeristy Hospital. The trial plans to enroll 300 participants.